[{"id":"5323a028-fdf5-4f10-ae90-a8fb6299a082","acronym":"","url":"https://clinicaltrials.gov/study/NCT02584920","created_at":"2021-01-18T12:32:23.897Z","updated_at":"2024-07-02T16:36:10.791Z","phase":"Phase 1/2","brief_title":"A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma","source_id_and_acronym":"NCT02584920","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Hanlikang (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2022-05-09"},{"id":"e9fac281-5795-4726-a5a7-c48c97194e99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03218072","created_at":"2021-01-18T15:52:43.838Z","updated_at":"2024-07-02T16:36:10.764Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas","source_id_and_acronym":"NCT03218072","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD19 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hanlikang (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/04/2014","start_date":" 05/04/2014","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 01/31/2015","study_completion_date":" 01/31/2015","last_update_posted":"2022-05-09"},{"id":"ea155fa1-a638-49b2-93aa-48e5245ebee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02787239","created_at":"2021-01-18T13:40:26.295Z","updated_at":"2024-07-02T16:36:10.757Z","phase":"Phase 3","brief_title":"Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL","source_id_and_acronym":"NCT02787239","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hanlikang (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2022-05-09"},{"id":"164bc4ff-cf84-4987-9b4e-18c106002dc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04671420","created_at":"2021-01-19T20:44:41.360Z","updated_at":"2024-07-02T16:36:37.276Z","phase":"Phase 3","brief_title":"Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.","source_id_and_acronym":"NCT04671420","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Hanlikang (rituximab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2020-12-16"},{"id":"20785ae3-3d6b-4ea1-aa47-c54aa253e07c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491721","created_at":"2021-01-18T21:34:45.439Z","updated_at":"2024-07-02T16:36:42.646Z","phase":"","brief_title":"Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL","source_id_and_acronym":"NCT04491721","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Hanlikang (rituximab biosimilar)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 407","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2020-07-29"}]